Study of the Antimicrobial Potential of the , , cf. , nov., , and against Gram-Positive, Gram-Negative Bacteria, and Mycobacteria.

The incidence of diseases brought on by resistant strains of micro-organisms, including tuberculosis, is rising globally as a result of the rapid rise in pathogenic micro-organism resistance to antimicrobial treatments. Secondary metabolites with potential for antibacterial activity are produced by cyanobacteria and microalgae. In this study, gram-positive (, ) and gram-negative (, , ) bacteria were isolated from pulmonary tuberculosis patients receiving long-term antituberculosis therapy. The antimicrobial potential of extracts from the cyanobacteria cf. , , , sp. nov., , and Rouchijajnen was evaluated. On mouse splenocytes and peritoneal macrophages, extracts of cyanobacteria and microalgae had inhibitory effects. In vitro studies have shown that cyanobacteria and microalgae extracts suppress the growth of bacteria and mycobacteria. At the same time, it has been demonstrated that cyanobacterial and microalgal extracts can encourage bacterial growth in a test tube. Additionally, the enhanced fucoxanthin fraction significantly reduced the development of bacteria in vitro. In a mouse experiment to simulate tuberculosis, the mycobacterial load in internal organs was considerably decreased by fucoxanthin. According to the information gathered, cyanobacteria and microalgae are potential sources of antibacterial compounds that can be used in the manufacturing of pharmaceutical raw materials.